Passage Bio, Inc. (NASDAQ:PASG – Get Rating) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 3,060,000 shares, a growth of 24.4% from the April 30th total of 2,460,000 shares. Currently, 11.6% of the company’s stock are sold short. Based on an average […]
Passage Bio (NASDAQ:PASG – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday, Zacks.com reports. The firm presently has a $2.00 price objective on the stock. Zacks Investment Research‘s price target points to a potential upside of 7.53% from the stock’s […]
Passage Bio, Inc. (NASDAQ:PASG – Get Rating) has received a consensus rating of “Hold” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts […]
Gamida Cell (NASDAQ:GMDA – Get Rating) and Passage Bio (NASDAQ:PASG – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability. Insider and Institutional Ownership 53.4% of Gamida Cell shares […]
Passage Bio, Inc. (NASDAQ:PASG – Get Rating) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,810,000 shares, a growth of 27.5% from the February 13th total of 1,420,000 shares. Based on an average daily volume of 311,500 shares, the […]